RecruitingNot applicableNCT04893564

Prognostic Value of Circulating Tumoral DNA After the First 6 Months of Treatment in Patients With Waldenström Macroglobulinemia

Studying Waldenström Macroglobulinemia

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Centre Hospitalier Universitaire, Amiens
Intervention
bone marrow sample(biological)
Enrollment
90 enrolled
Eligibility
18 years · All sexes
Timeline
2022 – 2028

Study locations (1)

Collaborators

Centre Henri Becquerel · University Hospital, Caen · University Hospital, Lille · Centre Hospitalier de Lens

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04893564 on ClinicalTrials.gov

Other trials for Waldenström Macroglobulinemia

Additional recruiting or active studies for the same condition.

See all trials for Waldenström Macroglobulinemia →

← Back to all trials